-
Given its lack of benefit, possible harms, and expense, magnesium sulfate should not be used for tocolysis.
-
RFA should be considered a first-line therapy even after the first episode of symptomatic AFL. There is a better long-term success rate, the same risk of subsequent AF, and fewer secondary effects.
-
Among adults diagnosed with heart failure who had no prior statin use, incident statin use was independently associated with lower risks of death and hospitalization among patients with or without coronary heart disease.
-
A meta-analysis of 10 studies of heparin used either for prophylaxis or for treatment suggests that venous thromboembolism related to heparin-induced thrombocytopenia occurs frequently in patients previously treated with unfractionated heparin, but uncommonly in those on low molecular weight heparin.
-
The stroke and death rates at one and 6 months were lower in patients with symptomatic carotid stenosis (> 60%) treated with endarterectomy versus stenting.
-
In this randomized study, patients with left-sided infective endocarditis and large vegetations who underwent valve replacement surgery within 48 hours of randomization had lower rates of embolic events and death from any cause after 6 months compared to those who underwent surgery later.
-
In this paper, the authors reviewed long-term survival data from a large population of out-of-hospital cardiac arrest patients who were discharged alive after their arrest. All patients who have a cardiac arrest in Seattle and King County, Washington, are entered into a registry organized to follow the Utstein guidelines for reporting cardiac arrest.
-
Chest pain presentations to the emergency department (ED) are common and very costly to the health care system. Although the event rates are low in patients with a low clinical risk profile, the price of a missed diagnosis is high.
-
After results of the pivotal NINDS intravenous thrombolysis (IV rtPA) trial were published in 1995, there has been a gradual extension of the time window from 3 hours to 4.5 hours, based on additional trials (ECASS II and III).
-
